Opdivo-Yervoy Combo Delays Disease Progression in Certain Patients with Advanced NSCLC, Study Shows

Opdivo-Yervoy Combo Delays Disease Progression in Certain Patients with Advanced NSCLC, Study Shows

Patients with advanced non-small cell lung cancer (NSCLC) whose tumors have high mutation burden lived longer without the disease progressing when receiving Opdivo (nivolumab) plus Yervoy (ipilimumab), compared to chemotherapy, a Phase 3 trial shows.

The pivotal CheckMate-227 study assessed the treatment as a first-line therapy. The results were independent of PD-L1 expression, a marker that often is used to predict responses to immune checkpoint inhibitors.

Based on an interim analysis for overall survival in patients whose tumors express PD-L1 — the study’s co-primary goal — the Data Monitoring Committee recommended that the study continue.

“TMB [tumor mutation burden] has emerged as an important biomarker for the activity of immunotherapy. For the first time, this Phase 3 study shows superior PFS [progression-free survival] with first-line combination immunotherapy in a predefined population of NSCLC patients with high TMB,” Matthew D. Hellmann, MD, study investigator and medical oncologist at Memorial Sloan Kettering Cancer Center, said in a press release.

The CheckMate-227 study(NCT02477826), currently recruiting participants, has enrolled more than 2,500 patients with advanced NSCLC, including non-squamous and squamous types. The study was set to show that first-line treatment with an Opdivo-based regimen is better than chemotherapy in advanced NSCLC patients.

The trial is divided in three parts — Parts 1a, 1b and 2 ­— each comparing specific treatment regimens.

In Part 1a, researchers are comparing the Opdivo-Yervoy combo and Opdivo alone with chemotherapy in patients with PD-L1-positive tumors. In Part 1b, Opdivo-Yervoy and Opdivo-chemotherapy combinations are being compared to chemotherapy alone in patients with PD-L1-negative tumors.

The main goals of Part 1 were to determine if Opdivo and Yervoy improved overall survival compared to chemotherapy in patients whose tumors expressed PD-L1, and if the regimen delayed disease progression in patients with high tumor burden, independent of their PD-L1 expression. High tumor burden is measured by the number of gene mutations in a tumor.

Part 2 will evaluate a combination of Opdivo and chemotherapy versus chemotherapy alone in a broad population of patients. The main outcome is overall survival.

Bristol-Myers is collaborating with Foundation Medicine and may soon seek regulatory approval for a companion diagnostic test, called FoundationOne CDx, that assesses a tumor’s mutational burden to identify NSCLC patients most likely to respond to Opdivo plus Yervoy as first-line treatment.

“CheckMate-227 showed that TMB is an important, independent predictive biomarker that can identify a population of first-line NSCLC patients who may benefit from the nivolumab plus ipilimumab combination,” Hellmann added.

“We believe these data from CheckMate-227 are a breakthrough in cancer research and a meaningful step forward in determining which first-line lung cancer patients may benefit most from the combination of Opdivo and Yervoy,” said Giovanni Caforio, MD, chairman and CEO, Bristol-Myers Squibb.

Latest Posts
  • Keytruda and SCLC
  • Affimed, AFM24-Tecentriq Combo
  • ilixadencel, cancer vaccine, update
  • Cytovia

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?